Virginija Danylaité Karrenbauer,Tomas Olsson,Lars Alfredsson et al.
Virginija Danylaité Karrenbauer et al.
Background: Late-onset multiple sclerosis (LOMS), defined as disease onset at or after 50 years, is increasingly recognized and associated with distinct features. However, it remains unclear whether LOMS differs etiologic...
Post-traumatic stress disorder in people with multiple sclerosis: A narrative review [0.03%]
多发性硬化患者的创伤后应激障碍：叙事综述
David E Freedman,Jiwon Oh,Anthony Feinstein
David E Freedman
Psychiatric comorbidities are common in people with multiple sclerosis (pwMS). Yet, post-traumatic stress disorder (PTSD) has received little attention to date. Grounded in an emerging literature on the impact of trauma on pwMS, this Topica...
Borrelia miyamotoi meningoradiculitis in multiple sclerosis patients treated with B-cell-depleting therapies [0.03%]
接受B细胞耗竭疗法的多发性硬化患者中发现Borrelia miyamotoi脑膜脑炎
Ricardo Soares-Dos-Reis,André Silva-Pinto
Ricardo Soares-Dos-Reis
Borrelia miyamotoi meningoradiculitis complicating ocrelizumab treatment for multiple sclerosis: A report of three cases [0.03%]
伯氏疏螺旋体脑膜角膜炎并发奥瑞珠单抗治疗多发性硬化症：三例报告
Philippe Nicolas,Ysoline Beigneux,Anne-Marie Guennoc et al.
Philippe Nicolas et al.
Ocrelizumab is an anti-CD20 monoclonal antibody that is highly effective in multiple sclerosis (MS) but is associated with an increased risk of opportunistic infections that may be difficult to diagnose. We report three MS patients treated ...
Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study [0.03%]
口服克拉屈滨片治疗的长期疗效：MAGNIFY-MS延展研究的结果
Nicola De Stefano,Patrick Vermersch,Heinz Wiendl et al.
Nicola De Stefano et al.
Background: The Phase IV MAGNIFY-MS Extension study evaluated the long-term efficacy and durability of cladribine tablets (CladT) in participants with highly active relapsing multiple sclerosis (RMS) during treatment-free...
Testing the construct validity of real-world digital mobility outcomes in multiple sclerosis [0.03%]
检验多发性硬化症中现实世界数字化结局的构念效度
Gavin Brittain,Michael Long,Ellen Buckley et al.
Gavin Brittain et al.
Background: Wearable devices can measure real-world mobility and generate metrics known as digital mobility outcomes (DMOs). For people with multiple sclerosis (pwMS), these DMOs have not been clinically validated. This s...
Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study [0.03%]
MSBase真实世界研究中的癌症诊断后化疗暴露患者的多发性硬化症预后
Cassie Nesbitt,Paul Sanfilippo,Chao Zhu et al.
Cassie Nesbitt et al.
Background and objective: As more people with multiple sclerosis (MS) survive cancer, questions about MS management after cancer are increasingly relevant. This study aimed to describe post-cancer treatment patterns and M...
Association between pregnancy timing and disability outcomes in women with mild relapse-onset multiple sclerosis [0.03%]
轻型复发发作性多发硬化女性患者怀孕时机与残疾预后之间的关系
Jessica Shipley,Chao Zhu,Paul G Sanfilippo et al.
Jessica Shipley et al.
Background: Pregnancy does not adversely affect disability outcomes in women with multiple sclerosis (MS). However, it remains uncertain whether pregnancy is associated with slower disability accumulation, and whether thi...
Controversies in MS: MS phenotypes should be abandoned in favour of a continuous disease spectrum model - YES [0.03%]
多发性硬化争论：应放弃MS表型而采用连续疾病谱模型
Sammita Satyanarayan,Fred D Lublin
Sammita Satyanarayan